• Citer

EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.

par Lalami, Yassine ;Specenier, Pol M;Awada, Ahmad ;Lacombe, Denis;Liberatoscioli, Cecilia;Fortpied, Catherine;El-Hariry, Iman;Bogaerts, Jan;Andry, Guy ;Langendijk, Johannes A;Vermorken, Jan B
Référence Radiotherapy and oncology, 105, 2, page (238-240)
Publication Publié, 2012-11

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.
Auteur:	Lalami, Yassine; Specenier, Pol M; Awada, Ahmad; Lacombe, Denis; Liberatoscioli, Cecilia; Fortpied, Catherine; El-Hariry, Iman; Bogaerts, Jan; Andry, Guy; Langendijk, Johannes A; Vermorken, Jan B
Informations sur la publication:	Radiotherapy and oncology, 105, 2, page (238-240)
Statut de publication:	Publié, 2012-11
Sujet CREF:	Cancérologie
Mots-clés:	Chemoradiation
	Head and neck cancer
	Induction chemotherapy
	Lapatinib
Note générale:	Journal Article
	Research Support, Non-U.S. Gov't
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0167-8140
	info:doi/10.1016/j.radonc.2012.08.006
	info:pii/S0167-8140(12)00357-X
	info:scp/84871330978
	info:pmid/22989664